Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGC Stock Forecast 2025-2026
$366.01
Current Price
$4.76B
Market Cap
Buy 9
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to RGC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
RGC Price Momentum
+294.1%
1 Week Change
+908.8%
1 Month Change
+6,482.9%
1 Year Change
+7,309.1%
Year-to-Date Change
-3.7%
From 52W High of $380.00
+11,979.5%
From 52W Low of $3.03
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Regencell (RGC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RGC and similar high-potential opportunities.
Latest RGC Stock Price Targets & Analyst Predictions
RGC has shown a year-to-date change of 7,309.1% and a 1-year change of 6,482.9%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for RGC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGC Analyst Ratings
9
Buy
5
Hold
1
Sell
RGC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $366.01
Latest RGC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 2, 2018 | B. Riley Securities | Eric Wold | Neutral | Downgrade | $0.00 |
| Dec 6, 2017 | MoffettNathanson | Robert Fishman | Neutral | Upgrade | $0.00 |
| Dec 6, 2017 | RBC Capital | Leo Kulp | Sector Perform | Downgrade | $0.00 |
| Dec 6, 2017 | Loop Capital | David Miller | Hold | Downgrade | $0.00 |
| Dec 6, 2017 | Macquarie | Chad Beynon | Neutral | Downgrade | $0.00 |
| Dec 5, 2017 | Wedbush | Michael Pachter | Neutral | Downgrade | $0.00 |
| Oct 26, 2017 | RBC Capital | Leo Kulp | Outperform | Upgrade | $0.00 |
| Oct 26, 2017 | Morgan Stanley | James Luan | Equal-Weight | Maintains | $18.00 |
| Oct 25, 2017 | B. Riley Securities | Eric Wold | Buy | Maintains | $24.75 |
| Oct 23, 2017 | Loop Capital | David Miller | Buy | Maintains | $24.00 |
| Oct 18, 2017 | B. Riley Securities | Eric Wold | Buy | Maintains | $24.00 |
| Sep 28, 2017 | Credit Suisse | Omar Sheikh | Underperform | Maintains | $13.00 |
| Jul 27, 2016 | JP Morgan | Neutral | Maintains | $23.00 | |
| Mar 15, 2016 | Credit Suisse | Neutral | Maintains | $20.00 | |
| Feb 10, 2016 | FBR Capital | Market Perform | Maintains | $18.00 | |
| Oct 15, 2015 | Morgan Stanley | Underweight | Downgrade | $18.00 | |
| Aug 21, 2015 | FBR Capital | Market Perform | Maintains | $20.00 | |
| Mar 10, 2015 | Topeka Capital | Hold | Maintains | $24.00 | |
| Feb 13, 2015 | JP Morgan | Neutral | Maintains | $20.00 | |
| Jan 8, 2015 | JP Morgan | Neutral | Maintains | $21.00 |
Regencell Bioscience Holdings Ltd. (RGC) Competitors
The following stocks are similar to Regencell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RGC
Regencell
mkt cap
4.76B
Regencell Bioscience Holdings Ltd. (RGC) Financial Data
Regencell Bioscience Holdings Ltd. has a market capitalization of $4.76B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -43.2%.
Valuation Metrics
Market Cap
$4.76B
Enterprise Value
$4.75B
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.2%
Current Ratio
41.9x
Debt/Equity
1.0x
ROE
-43.2%
ROA
-28.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Regencell Bioscience Holdings Ltd. (RGC) Business Model
About Regencell Bioscience Holdings Ltd.
What They Do
Biotechnology company focused on TCM for neurocognitive disorders.
Business Model
The company develops and commercializes Traditional Chinese Medicine (TCM) integrated formulas aimed at treating neurocognitive disorders like ADHD and ASD. By leveraging both traditional practices and modern scientific research, it targets significant healthcare demands in pediatric and adult sectors, generating revenue through the sale of these innovative treatment solutions.
Additional Information
Regencell's unique approach of combining ancient healing methods with scientific validation positions it as a potential leader in the biopharmaceutical industry. This strategy not only addresses unmet medical needs but also aligns with growing market interests in integrative medical therapies.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
12
CEO
Mr. Yat-Gai Au
Country
Hong Kong
IPO Year
2021
Website
www.regencellbioscience.comRegencell Bioscience Holdings Ltd. (RGC) Latest News & Analysis
Latest News
Quick Summary
Regencell Bioscience (NASDAQ: RGC), a drug manufacturer focused on traditional Chinese medicine for neurocognitive disorders, saw its shares surge on Tuesday, possibly attracting speculative interest.
Why It Matters
Regencell Bioscience's surge suggests growing interest in alternative therapies, potentially indicating market volatility and opportunities for speculative trading in niche sectors.
Source: InvestorPlace
Market Sentiment:
Positive
Quick Summary
Regencell Bioscience Holdings (Nasdaq: RGC) reported interim results from its second efficacy trial using Traditional Chinese Medicine for ADHD and ASD, aiming to alleviate economic and parental burdens.
Why It Matters
Regencell's trial results could influence stock performance by indicating potential market demand for its TCM treatments for ADHD and ASD, impacting revenue projections and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Regencell Bioscience, focused on Traditional Chinese Medicine, saw Chairman and CEO Yat-Gai Au buy over $5.9 million in RGC shares, indicating strong personal investment in the company.
Why It Matters
Regencell's CEO's substantial share purchase signals confidence in the company's future, potentially boosting investor sentiment and stock value.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Regencell Bioscience Holdings (NASDAQ: RGC) reported results from its EARTH trials, showing 94.1% and 97.3% symptom elimination in trials A and B, respectively, with 88 patients combined.
Why It Matters
Regencell's EARTH trial results show high efficacy in symptom elimination, potentially boosting investor confidence in its marketability and future stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Concerns about a potential U.S. recession are rising as inflation reached 8.5% in March, alongside increasing interest rates and an inverted yield curve in the bond market.
Why It Matters
Rising inflation, increasing interest rates, and an inverted yield curve signal potential economic slowdown, affecting market confidence and investment strategies.
Source: Benzinga
Market Sentiment:
Positive
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
2 years ago
Quick Summary
Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced that Chairman and CEO Yat-Gai Au has purchased ordinary shares in the company, which focuses on Traditional Chinese Medicine for neurocognitive disorders.
Why It Matters
Insider purchases can signal confidence in a company's future prospects, potentially attracting investor interest and influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RGC Stock
What is Regencell Bioscience Holdings Ltd.'s (RGC) stock forecast for 2025?
Analyst forecasts for Regencell Bioscience Holdings Ltd. (RGC) are not currently available. The stock is trading at $366.01.
Is RGC stock a good investment in 2025?
According to current analyst ratings, RGC has 9 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $366.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGC stock?
Price predictions from Wall Street analysts for RGC are not currently available. The stock is trading at $366.01.
What is Regencell Bioscience Holdings Ltd.'s business model?
The company develops and commercializes Traditional Chinese Medicine (TCM) integrated formulas aimed at treating neurocognitive disorders like ADHD and ASD. By leveraging both traditional practices and modern scientific research, it targets significant healthcare demands in pediatric and adult sectors, generating revenue through the sale of these innovative treatment solutions.
What is the highest forecasted price for RGC Regencell Bioscience Holdings Ltd.?
Price targets from Wall Street analysts for RGC are not currently available. The stock is trading at $366.01.
What is the lowest forecasted price for RGC Regencell Bioscience Holdings Ltd.?
Price targets from Wall Street analysts for RGC are not currently available. The stock is trading at $366.01.
What is the overall RGC consensus from analysts for Regencell Bioscience Holdings Ltd.?
The overall analyst consensus for RGC is bullish. Out of 9 Wall Street analysts, 9 rate it as Buy, 5 as Hold, and 1 as Sell.
How accurate are RGC stock price projections?
Stock price projections, including those for Regencell Bioscience Holdings Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 12:10 PM UTC